Ischemic Preconditioning Decreases Leukotriene C4 Production during Hepatic Ischemia Reperfusion Injury in Rats

[1]

DING Baofeng, WANG Xiaoshuang, WANG Fang, YU Jia. Pathological changes and metabolome analysis of liver in obese mouse models [J]. Basic & Clinical Medicine, 2024, 44(5): 699-704.

[2]

AN Qi, QI Guangzhao, HAN Chao. Aucubin inhibits the proliferation of human hepatocellular carcinoma cells line HepG2 [J]. Basic & Clinical Medicine, 2024, 44(3): 333-338.

[3]

GUO Xin, JI Mengdie, WANG Qi, LI Xueyuan, CHEN Yang. Identification of the effect of cisplatin on the transcriptome of human hepatocellular carcinoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(3): 352-360.

[4]

[5]

XIAO Yanxin, LIU Yan, XU Lingling, ZHOU Yaru. Research progress on the role of ferroptosis in the pathogenesis of non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2024, 44(2): 260-264.

[6]

[7]

HU Ning, HUANG Hannian, XIA Daozong. Comparison of acute immunological liver injury models in two different species of mice [J]. Basic & Clinical Medicine, 2023, 43(9): 1364-1368.

[8]

YANG Yaqian, PAN Yanfang, QU Mengyang, FANG Yan, YING Xiaoping, ZHANG Meiqian, WEI Jing. Progress of research on the role of exosomes in the occurrence and development of liver precancerous lesions [J]. Basic & Clinical Medicine, 2023, 43(9): 1453-1456.

[9]

[10]

WANG Xinrui, QIN Yan. Research advances of Ghrelin in metabolic diseases [J]. Basic & Clinical Medicine, 2023, 43(8): 1299-1303.

[11]

HAO Dandan, ZHANG Lei, BAI Chunying. Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2023, 43(8): 1317-1321.

[12]

LI Zhuoting, SHANG Yingxu, WANG Haiyan, JIANG Qiao, DING Baoquan, LI Jing, ZHAO Chunhua. Mesenchymal stem cell-engineered DNA nanostructures and the application in targeted delivery to the lungs of mice [J]. Basic & Clinical Medicine, 2023, 43(7): 1110-1116.

[13]

LIU Lei, DING Lan, YUAN Yuan, YE Jing. Advance on iron overload in liver diseases [J]. Basic & Clinical Medicine, 2023, 43(6): 990-993.

[14]

CHENG Qi, LI Ning, YU Kangkang, SHI Guangfeng. Chemokine CX3CL1 has potential anti-fibrosis effect in mouse liver fibrosis [J]. Basic & Clinical Medicine, 2023, 43(12): 1792-1795.

[15]

HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong. Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease [J]. Basic & Clinical Medicine, 2023, 43(10): 1594-1598.

PDF